Evaxion’s AI-Immunology™ platform validated in multiple trials

Data from three different clinical studies highlight the impressive capability of the AI-Immunology™ platform in identifying clinically relevant vaccine targets. The most significant outcomes were produced by the top-ranked AI-Immunology™ vaccine targets, demonstrating a direct connection between AI-driven vaccine design and real-world evidence. This emphasizes the platform’s exceptional potential in selecting effective vaccine targets. The ongoing generation of pertinent clinical data allows for continuous improvement of AI-Immunology™, thereby expanding its commercial potential.

COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company focusing on AI-Immunology™ powered vaccines, has gathered evidence from three different clinical trials validating the vaccine target predictions of its AI platform.

Evaxion has developed three personalized cancer vaccine candidates using its AI-Immunology™ platform. Two of these – EVX-01 and EVX-02 – have completed phase 1 clinical testing, and EVX-01 is currently in phase 2, while the third candidate – EVX-03 – is ready for investigational new drug (IND) application. The AI-Immunology™ platform identifies cancer vaccine targets, known as neoantigens, and assigns a prediction score indicating the likelihood of each target to induce a specific immune response against the tumor.

In all three clinical trials, a statistically significant correlation was found between the AI-Immunology™ prediction scores and the immune responses measured in patients, with the most robust responses generated by the vaccine targets with the highest prediction scores. Additionally, in one trial where it was assessed, a significant correlation was demonstrated between AI-Immunology™ prediction scores and Progression Free Survival (PFS) in patients. This highlights the platform's ability to identify vaccine targets with meaningful clinical impact.

“We are proud to have collected such strong clinical data documenting the unique predictive capabilities of the AI-Immunology™ platform across several clinical trials. The correlation between the platform’s prediction score and clinical outcome is unique and provides very solid guidance for the further development of personalized cancer vaccines based upon AI-Immunology™. Generating highly relevant clinical data is very important for our ability to apply constant learning loops, allowing for the continuous development of AI-Immunology™,” says Christian Kanstrup, CEO of Evaxion.

AI-Immunology™ is a scalable and adaptable artificial intelligence technology platform at the forefront of vaccine discovery for infectious diseases and cancers. By integrating the collective power of proprietary AI models PIONEER™, EDEN™, RAVEN™, and ObsERV™, the platform can model the complexity of the patient’s immune system. AI-Immunology™ advanced computational modeling swiftly and uniquely identifies, predicts, and designs vaccine candidates, revolutionizing the landscape of immunotherapy by offering a holistic and personalized approach to combat fast-evolving pathogens and malignant cells.

Evaxion Biotech A/S is a pioneering TechBio company based on its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based on AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options.